Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
stocks
Strong start to the year for cheap ASX share
Investors are ignoring a strong long-term outlook.
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,686.30 | 8.30 | -0.10% |
| CAC 40 | 7,989.44 | 8.37 | 0.10% |
| DAX 40 | 23,091.87 | 186.98 | -0.80% |
| Dow JONES (US) | 46,245.41 | 493.15 | 1.08% |
| FTSE 100 | 9,531.01 | 3.36 | 0.04% |
| HKSE | 25,220.02 | 615.55 | -2.38% |
| NASDAQ | 22,273.08 | 195.03 | 0.88% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,419.40 | 20.00 | -0.15% |
| S&P 500 | 6,602.99 | 64.23 | 0.98% |
| S&P/ASX 200 | 8,416.50 | 0.00 | 0.00% |
| SSE Composite Index | 3,834.89 | 96.16 | -2.45% |